Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 192

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis

Liu, Shan, Cipriano, Lauren E., Holodniy, Mark, Owens, Douglas K., Goldhaber-Fiebert, Jeremy D. · 2012 · Annals of Internal Medicine

Abstract

BACKGROUND: Chronic hepatitis C virus is difficult to treat and affects approximately 3 million Americans. Protease inhibitors increase the effectiveness of standard therapy, but they are costly. A genetic assay may identify patients most likely to benefit from this treatment advance. OBJECTIVE: To assess the cost-effectiveness of new protease inhibitors and an interleukin (IL)-28B genotyping assay for treating chronic hepatitis C virus. DESIGN: Decision-analytic Markov model. DATA SOURCES: Published literature and expert opinion. TARGET POPULATION: Treatment-naive patients with chronic, genotype 1 hepatitis C virus monoinfection. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Strategies are defined by the use of IL-28B genotyping and type of treatment (standard therapy [pegylated interferon with ribavirin]; triple therapy [standard therapy and a protease inhibitor]). Interleukin-28B-guided triple therapy stratifies patients with CC genotypes to standard therapy and those with non-CC types to triple therapy. OUTCOME MEASURES: Discounted costs (in 2010 U.S. dollars) and quality-adjusted life-years (QALYs); incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: For patients with mild and advanced fibrosis, universal triple therapy reduced the lifetime risk for hepatocellular carcinoma by 38% and 28%, respectively, and increased quality-adjusted life expectancy by 3% and 8%, respectively, compared with standard therapy. Gains from IL-28B-guided triple therapy were smaller. If the protease inhibitor costs $1100 per week, universal triple therapy costs $102,600 per QALY (mild fibrosis) or $51,500 per QALY (advanced fibrosis) compared with IL-28B-guided triple therapy and $70,100 per QALY (mild fibrosis) and $36,300 per QALY (advanced fibrosis) compared with standard therapy. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to the cost of protease inhibitors and treatment adherence rates. LIMITATION: Data on the long-term comparative effectiveness of the new protease inhibitors are lacking. CONCLUSION: Both universal triple therapy and IL-28B-guided triple therapy are cost-effective when the least-expensive protease inhibitor are used for patients with advanced fibrosis. PRIMARY FUNDING SOURCE: Stanford University.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.7326/0003-4819-156-4-201202210-00005

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 192

Metadata

Authors
Liu, S., Cipriano, L. E., Holodniy, M., Owens, D. K., & Goldhaber-Fiebert, J. D.
Venue
Annals of Internal Medicine
Published
2012-02-21
Volume
156
Issue
4
Pages
279-290
ISSN
  • 0003-4819 (ISSN-L)
  • 1539-3704
OpenAlex
W2022967348
Cited by
192
References
1
FWCI
21.49
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis. https://app.cochat.ai/papers/10.7326/0003-4819-156-4-201202210-00005
The paper
Liu, S., Cipriano, L. E., Holodniy, M., Owens, D. K., & Goldhaber-Fiebert, J. D. (2012). New Protease Inhibitors for the Treatment of Chronic Hepatitis C: A Cost-Effectiveness Analysis. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-156-4-201202210-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.